10-Q: Walgreens Boots Alliance Reports Q3 2025 Results Amidst Strategic Overhaul and Pending Merger

Walgreens Boots Alliance reported a reduced net loss for the nine months ended May 31, 2025, driven by lower impairment charges, but saw declines in adjusted earnings and U.S. retail sales, as the company progresses with its Footprint Optimization Program and a proposed merger.

Summary

• For the nine months ended May 31, 2025, Walgreens Boots Alliance reported a net loss attributable to the company of $3.293 billion, a significant improvement from the $5.631 billion net loss in the prior year, primarily due to lower goodwill impairment charges.
• Adjusted net earnings attributable to the company for the nine months decreased by 38.8% to $1.317 billion, down from $2.152 billion in the prior year.
• Diluted net loss per common share was $3.81, an improvement from $6.53 in the prior year, while adjusted diluted net earnings per common share fell to $1.52 from $2.49.
• The company recorded total goodwill, intangible, and long-lived asset impairment charges of $5.432 billion for the nine months ended May 31, 2025, primarily related to VillageMD ($3.0 billion), U.S. Retail Pharmacy ($2.0 billion), CareCentrix ($178 million), and Boots intangible assets ($115 million).
• Total sales for the nine months increased by 6.3% to $117.034 billion.
• The U.S. Retail Pharmacy segment's sales increased by 6.6% to $91.961 billion, driven by pharmacy sales growth (+10.4%), but retail sales declined by 5.7%.
• The International segment's sales increased by 6.1% to $18.657 billion, with Boots UK retail sales growing strongly and pharmaceutical wholesale sales increasing in Germany.
• The U.S. Healthcare segment's sales increased by 3.1% to $6.427 billion, with growth in CareCentrix (+11.3%) and Shields (+28.1%) partially offset by a decline in VillageMD sales (-1.7%).
• The company is executing a Footprint Optimization Program to close approximately 900 to 1,000 underperforming stores, primarily in the U.S., by the end of fiscal 2027, with 423 stores already closed.
• A proposed merger agreement was entered into on March 6, 2025, with Blazing Star Parent, LLC, an affiliate of Sycamore Partners, where shareholders will receive $11.45 in cash and one Divested Asset Proceed Right (DAP Right) per share, with the merger expected to close in Q3 or Q4 calendar year 2025.
• The company suspended its quarterly cash dividend on January 30, 2025, to strengthen its balance sheet, reduce debt, and improve free cash flow.
• Total debt was reduced from $9.549 billion as of August 31, 2024, to $7.366 billion as of May 31, 2025, partly due to proceeds from a new $2.5 billion Accounts Receivable Facility used to repay existing debt.
• The company settled opioid-related litigation with the DOJ for $300 million over six years plus a contingent $50 million payment, and a commercial arbitration award with Everly Health Solutions for $595 million.

Sentiment

Score: 4

Explanation: The company is in a significant turnaround phase with ongoing restructuring, substantial impairment charges, and a dividend suspension, indicating continued financial challenges. While GAAP losses are reduced, adjusted earnings are down, and the pending merger introduces both potential resolution and uncertainty. The overall picture is one of a company still navigating a difficult transition.

Positives

• Net loss for the nine months ended May 31, 2025, significantly decreased to $3.293 billion from $5.631 billion in the prior year, indicating a reduction in the rate of loss.
• Total sales increased by 6.3% for the nine months ended May 31, 2025, reaching $117.034 billion.
• The U.S. Retail Pharmacy segment saw a 10.4% increase in pharmacy sales and a 13.2% increase in comparable pharmacy sales, driven by branded drug inflation and prescription volume.
• The International segment's adjusted operating income increased by 9.3% to $615 million, reflecting strong retail performance in Boots UK and market growth in Germany.
• Boots.com sales grew by 23.1% (19.8% constant currency), now representing nearly 20% of Boots UK total retail sales.
• The U.S. Healthcare segment's adjusted operating income improved significantly to $196 million from a loss of $151 million in the prior year, and Adjusted EBITDA improved to $314 million from $1 million.
• Shields Health Solutions sales increased by 28.1%, driven by expansion of existing partnerships.
• CareCentrix sales increased by 11.3% due to higher fee-for-service volume.
• The company successfully reduced total debt from $9.549 billion to $7.366 billion.
• The sale of the remaining investment in BrightSpring Health Services generated approximately $610 million in proceeds for the nine months ended May 31, 2025.
• The company settled VPF derivative contracts and sold Cencora common stock, generating cash proceeds and pre-tax gains, and reclassified its Cencora investment to fair value after its ownership fell below 5%.

Negatives

• Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. decreased by 38.8% to $1.317 billion for the nine months ended May 31, 2025.
• Adjusted diluted net earnings per common share decreased by 39.0% to $1.52 for the nine months ended May 31, 2025.
• The U.S. Retail Pharmacy segment's retail sales decreased by 5.7% for the nine months, with comparable retail sales down 3.2%, impacted by weaker sales in discretionary categories and a challenging consumer spending environment.
• The International segment's pharmacy sales decreased by 1.3% due to adverse impacts from National Health Service volume and reimbursement levels, and store closures.
• VillageMD sales decreased by 1.7% due to lower risk-based and fee-for-service revenue, including the impact of clinic closures.
• The company suspended its quarterly cash dividend to stockholders, impacting income-focused investors.
• Significant legal settlements, including $300 million for the DOJ opioid lawsuit and $595 million for the Everly Health Solutions arbitration, represent substantial cash outflows.
• The company continues to face ongoing litigation related to opioid abuse, usual and customary pricing, and securities claims regarding VillageMD investment and controlled substances dispensing practices.
• The company's credit ratings were downgraded below investment grade in fiscal 2024, which may increase the cost of new financing and reduce access to capital markets.

Risks

• Uncertainties related to the proposed merger, including the risk that it may not be completed in a timely manner or at all, failure to satisfy conditions (stockholder and regulatory approvals), and potential termination fees.
• The ability of affiliates of Sycamore Partners to obtain necessary financing for the merger.
• The effect of the merger announcement on the company's business relationships, operating results, and ability to retain key personnel and maintain relationships with partners and customers.
• The risk that Divested Asset Proceed Rights (DAP Rights) may result in less-than-anticipated payments or no payments, expiring valueless.
• The impact of opioid-related claims and litigation settlements, which continue to be substantial and involve ongoing legal proceedings.
• Adverse global macroeconomic conditions, including inflation, high interest rates, labor shortages, and supply chain disruptions, affecting operations and financial results.
• The financial performance of equity method investees and consolidated subsidiaries in the U.S. Healthcare segment, particularly VillageMD, which has undergone significant impairment charges.
• The amount of future goodwill, intangible, and other long-lived asset impairment charges, which are based on estimates of future performance and market conditions.
• Changes in vendor, payor, and customer relationships and terms, and associated reimbursement pressure in the pharmacy business.
• The company's ability to successfully execute its strategic initiatives, including the Footprint Optimization Program and efforts to stabilize pharmacy margins and re-evaluate retail sales strategy.
• The ongoing sale process for certain VillageMD assets, with no assurance that a sale will be completed on acceptable terms or at all.
• Potential litigation relating to the proposed merger, which could delay or prevent the transaction and negatively impact the company's business.
• Restrictions on the conduct of the company's business under the terms of the Merger Agreement, which may prevent certain strategic actions.

Future Outlook

The company expects to continue focusing on its strategic review, building its core retail and specialty pharmacy business, leveraging current assets, and expanding business partner relationships. Store closures under the Footprint Optimization Program are expected to continue through fiscal 2027. The proposed merger is anticipated to close in the third or fourth quarter of calendar year 2025, after which the company will become private. The company aims to stabilize pharmacy margins and anticipates the retail environment to remain challenging. Remaining contributions of approximately $450 million to the Boots Pension Plan are expected by the end of fiscal 2026.

Management Comments

• "The decision reflects managements ongoing efforts to evaluate and refine the Companys capital allocation policy in alignment with the Companys broader long-term turnaround efforts." (Regarding dividend suspension)
• "The Company believes it is on track to deliver benefits to cash flow from the Footprint Optimization Program that will exceed cash closure costs."

Industry Context

Walgreens Boots Alliance operates in a challenging retail pharmacy environment, facing declining discretionary spending and a weaker cough, cold, and flu season impacting retail sales. The company is actively restructuring its physical footprint to adapt to evolving demographic trends and consumer behavior, a strategy also pursued by other industry peers. Despite retail headwinds, the pharmacy sector continues to see growth, driven by branded drug inflation and demand for services. The U.S. Healthcare segment is expanding its value-based care and specialty pharmacy services, aligning with broader healthcare industry trends towards integrated care and cost management, though VillageMD faces its own challenges. The company's significant legal settlements related to opioid claims reflect an ongoing industry-wide issue impacting pharmaceutical distributors and retailers.

Comparison to Industry Standards

• The document mentions that the Footprint Optimization Program aims to 'close the competitive gap with peers that have taken similar initiatives over the past years,' implying that other major retail pharmacy chains have also undergone store rationalization, but does not name specific comparable companies or provide their results.
• In the context of goodwill impairment, the company refers to 'a reduction in the multiples for publicly traded peer companies' but does not specify which companies or their performance metrics for direct comparison.

Corporate Governance

Legal Proceedings

• The company has accrued a total of $6.2 billion liability as of May 31, 2025, associated with the Multistate Settlement Agreement and other opioid-related claims and litigation settlements.
• Settled litigation with the U.S. Department of Justice (DOJ) related to dispensing of controlled substances for $300 million over six years plus a contingent $50 million payment, and entered into a related Memorandum of Agreement with the DEA and a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services.
• Settled a commercial arbitration award with Everly Health Solutions for $595 million, paid in February 2025, following a federal court upholding the arbitration award.
• A putative class action lawsuit (Russo et al. v. Walgreen Co. et al.) alleging overcharging for prescription drugs by not submitting correct usual and customary prices has reached a settlement agreement, with preliminary court approval granted on November 19, 2024. The company has accrued $150 million for all usual and customary pricing litigation.
• Defending against multiple actions in federal courts (MDL No. 2804 in N.D. Ohio) and state courts concerning the impacts of widespread opioid abuse, with a trial date set for a Florida case in September 2025.
• Defending against consolidated putative class action lawsuits (Bhaila v. Walgreens Boots Alliance, Inc.; Westchester Putnam Counties Heavy & Highway Laborers Local 60 Benefits Fund v Walgreens Boots Alliance, Inc.) alleging materially false and misleading statements regarding the VillageMD investment.
• Defending against consolidated shareholder derivative suits (Tobias v. Wentworth et al.; Hollin v. Wentworth et al.; Lovoi v. Wentworth et al.) alleging breaches of fiduciary duties related to false and misleading statements about internal controls and expected performance.
• Defending against a shareholder derivative suit (Switter v. Wentworth, et al.) alleging violations of securities laws, breaches of fiduciary duties, and unjust enrichment related to misleading statements and share repurchases at artificially inflated prices.
• Defending against a putative class action lawsuit (Klein v. Walgreens Boots Alliance, Inc.) alleging materially false and misleading statements concerning compliance with laws governing controlled substances dispensing, following the DOJ lawsuit.

Related Party Transactions

• The company has a long-term pharmaceutical distribution agreement with Cencora, with net purchases of $58.843 billion for the nine months ended May 31, 2025, and trade accounts payable, net of receivables, of $8.943 billion as of May 31, 2025.
• On March 6, 2025, the company entered into a Merger Agreement with Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Stefano Pessina, Executive Chairman and a significant shareholder (approximately 17% ownership), and his holding company, entered into a voting agreement to vote in favor of the merger and a reinvestment agreement to reinvest their cash consideration plus an incremental cash investment into the acquiring company.
• As of June 9, 2025, Cencora is no longer considered a related party transaction as the company's ownership fell below 5% and it was no longer entitled to designate a director to the Cencora Board.

Stakeholder Impact

• Shareholders: Will receive $11.45 in cash and one Divested Asset Proceed Right (DAP Right) per share upon merger completion, providing a potential liquidity event but with uncertainty regarding the DAP Right value. The suspension of the quarterly cash dividend negatively impacts income-focused shareholders.
• Employees: The Footprint Optimization Program involves store closures and employee severance costs, indicating potential job reductions. The merger could also lead to changes in personnel and operations.
• Customers: Store closures under the Footprint Optimization Program may impact customer access to Walgreens retail pharmacy services in affected areas.
• Suppliers and Payors: The pending merger and strategic review could lead to renegotiations of existing business relationships or changes in terms.
• Creditors: The company's focus on strengthening its balance sheet and reducing debt, along with compliance with debt covenants, aims to reassure creditors. However, credit rating downgrades could increase future borrowing costs.
• Regulatory Authorities: Ongoing legal proceedings and settlements, particularly related to opioid dispensing and pricing, highlight continued scrutiny and compliance obligations.

Next Steps

• Continue execution of the Footprint Optimization Program, with store closures expected to progress through the remainder of fiscal 2025 and conclude by the end of fiscal 2027.
• Advance efforts to control costs by expanding centralized service capacity, using improved labor models, and optimizing micro-fulfillment centers.
• Work to stabilize pharmacy margins by contracting with partners that incorporate levers intended to lessen reimbursement risk.
• Accelerate various merchandising and inventory management initiatives in the second half of the fiscal year, including assortment optimization and inventory reinvestment.
• Continue to monetize non-core assets and manage liquidity.
• VillageMD is conducting an ongoing sale process for certain legacy Village Medical and Summit CityMD Holdco LLC assets.
• Hold a Special Meeting on July 11, 2025, for stockholders to vote on the adoption of the Merger Agreement.
• Complete the proposed merger, expected to occur in the third or fourth quarter of calendar year 2025, after which the company will become private.
• Make remaining contributions of approximately $450 million to the Boots Pension Plan by the end of fiscal 2026.

Key Dates

Recommendation

Keywords

Retail Pharmacy, Healthcare Services, SEC Filing, 10-Q, Financial Results, Merger Agreement, Goodwill Impairment, Store Closures, Dividend Suspension, Debt Reduction, Opioid Litigation, Cencora, VillageMD, Boots UK, Accounts Receivable Securitization, Strategic Review, Cost Management